Custom Search
News
Tuesday 08 January 2008
Auriga and MiddleBrook to co-promote oral antiskin infection drug
Auriga Laboratories has signed a co-promotion agreement with MiddleBrook Pharmaceuticals, pursuant to which Auriga will co-promote Keflex 750mg capsules to Primary Care Specialists in the US.
The co-promotion will begin during the first quarter of 2008. Cephalexin, the generic form of Keflex, is said to be the number-one recommended oral antibiotic therapy for uncomplicated skin and skin structure infections.
Philip Pesin, CEO of Auriga, said: "This agreement solidifies Auriga's commitment to enhance our product portfolio."
www.datamonitor.com